What is the appropriate Coumadin (warfarin) dose adjustment for a patient with an International Normalized Ratio (INR) of 1.8 who is currently taking 6mg of Coumadin (warfarin) three times a week?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Warfarin Dose Adjustment for INR 1.8

For a patient taking 6mg three times weekly (18mg total weekly) with an INR of 1.8, increase the total weekly dose by 10-15%, which translates to approximately 20-21mg per week, distributed as 7mg three times weekly or 6mg four times weekly. 1

Rationale for Dose Adjustment

The current INR of 1.8 falls just below the therapeutic range of 2.0-3.0 for most indications. 1, 2 This represents a minor deviation (≤0.5 below target), which requires a measured response rather than aggressive intervention.

Specific Dosing Algorithm

Based on established guidelines for subtherapeutic INR management:

  • INR 1.6-1.9: Increase weekly dose by 10% 1
  • Current weekly dose: 18mg (6mg × 3 days)
  • 10% increase: 18mg + 1.8mg = 19.8mg weekly (round to 20mg)
  • Practical distribution options:
    • Option 1: 7mg on three days per week (21mg total)
    • Option 2: 6mg on four days per week (24mg total) - if more aggressive approach needed
    • Option 3: Alternate 6mg and 7mg doses to achieve ~20mg weekly

Follow-Up Monitoring

  • Recheck INR in 1-2 weeks after dose adjustment 3, 1
  • For a single subtherapeutic INR with previously stable values, some guidelines suggest continuing the current dose and retesting, but given the INR is below 2.0, a modest increase is warranted 3
  • Once stable in therapeutic range, monitoring intervals can extend to 4-6 weeks 4

Important Considerations

No Bridging Therapy Required

Heparin bridging is NOT recommended for a single subtherapeutic INR, as it increases bleeding risk without clear benefit. 3 Even in high-risk patients with mechanical heart valves, thromboembolic event rates remain very low (0.4%) without bridging. 3

Patient-Specific Factors to Assess

Before implementing dose adjustment, verify:

  • Medication adherence: Confirm patient is actually taking prescribed doses 3
  • Dietary changes: Recent increases in vitamin K intake (leafy greens) can lower INR 4
  • New medications: Drug interactions are common with warfarin 4
  • Gastrointestinal issues: Diarrhea or decreased oral intake can affect INR 5
  • Intercurrent illness: Acute medical conditions may alter warfarin metabolism 6

Common Pitfalls to Avoid

  • Avoid overreacting to a single slightly low INR with excessive dose increases 3, 1
  • Do not use loading doses or make changes >20% of weekly dose for minor deviations 4
  • Avoid unnecessary bridging therapy which increases bleeding risk 3
  • Do not adjust dose if this is the first subtherapeutic reading and patient has been previously stable - consider retesting first 3

Special Populations

If this patient has a mechanical heart valve (particularly mitral position or older valve types), target INR may be 2.5-3.5 rather than 2.0-3.0, making this INR of 1.8 more significantly subtherapeutic and potentially warranting a 15% dose increase instead of 10%. 2, 7

References

Guideline

Warfarin Dose Adjustment Based on INR Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Subtherapeutic INR in Patients on Warfarin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Management and dosing of warfarin therapy.

The American journal of medicine, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.